688575 Stock Overview
Researches, develops, produces, sells, and services in vitro diagnostic instruments and reagents in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Shenzhen YHLO Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.46 |
| 52 Week High | CN¥28.27 |
| 52 Week Low | CN¥16.03 |
| Beta | 0.66 |
| 1 Month Change | -9.66% |
| 3 Month Change | -19.71% |
| 1 Year Change | -27.26% |
| 3 Year Change | -28.46% |
| 5 Year Change | n/a |
| Change since IPO | -63.99% |
Recent News & Updates
Shenzhen YHLO Biotech (SHSE:688575) Has A Pretty Healthy Balance Sheet
Nov 27
We Think That There Are More Issues For Shenzhen YHLO Biotech (SHSE:688575) Than Just Sluggish Earnings
Nov 06Slammed 25% Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575) Screens Well Here But There Might Be A Catch
Nov 04Estimating The Intrinsic Value Of Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575)
Oct 31Recent updates
Shenzhen YHLO Biotech (SHSE:688575) Has A Pretty Healthy Balance Sheet
Nov 27We Think That There Are More Issues For Shenzhen YHLO Biotech (SHSE:688575) Than Just Sluggish Earnings
Nov 06Slammed 25% Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575) Screens Well Here But There Might Be A Catch
Nov 04Estimating The Intrinsic Value Of Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575)
Oct 31Shenzhen YHLO Biotech (SHSE:688575) Is Reinvesting At Lower Rates Of Return
Oct 12Shenzhen YHLO Biotech Co., Ltd.'s (SHSE:688575) Price In Tune With Earnings
Aug 30Does Shenzhen YHLO Biotech (SHSE:688575) Have A Healthy Balance Sheet?
Jul 18Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575) Not Lagging Market On Growth Or Pricing
May 23Shenzhen YHLO Biotech's (SHSE:688575) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 01There Are Reasons To Feel Uneasy About Shenzhen YHLO Biotech's (SHSE:688575) Returns On Capital
Mar 19Shareholder Returns
| 688575 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -5.4% | -2.8% | -1.2% |
| 1Y | -27.3% | -9.2% | 11.8% |
Return vs Industry: 688575 underperformed the CN Medical Equipment industry which returned -9.2% over the past year.
Return vs Market: 688575 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 688575 volatility | |
|---|---|
| 688575 Average Weekly Movement | 7.6% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688575 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688575's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,776 | Yongbo Song | www.szyhlo.com |
Shenzhen YHLO Biotech Co., Ltd. researches, develops, produces, sells, and services in vitro diagnostic instruments and reagents in China and internationally. The company offers automatic chemiluminescence immunoassay analyzers, chemiluminescent immunoassay analyzers, and iModule automatic immunoassay pipelines; and automatic immunofluorescence staining systems, automatic immunofluorescence analysis systems, automatic western blotting analyzers, auto automatic western blot analyzers, and automatic western blotting instruments. It also provides UNION new generation immune analyzers; dry fluorescence immunoassay analyzers, vision automatic dynamic ESR analyzers, and vision dynamic ESR analyzers; and automated sample processing systems and intelligent laboratory information systems, as well as antigen detection and test kits.
Shenzhen YHLO Biotech Co., Ltd. Fundamentals Summary
| 688575 fundamental statistics | |
|---|---|
| Market cap | CN¥9.39b |
| Earnings (TTM) | CN¥288.64m |
| Revenue (TTM) | CN¥1.90b |
32.5x
P/E Ratio4.9x
P/S RatioIs 688575 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688575 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.90b |
| Cost of Revenue | CN¥734.78m |
| Gross Profit | CN¥1.17b |
| Other Expenses | CN¥878.60m |
| Earnings | CN¥288.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.51 |
| Gross Margin | 61.37% |
| Net Profit Margin | 15.18% |
| Debt/Equity Ratio | 32.4% |
How did 688575 perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield54%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenzhen YHLO Biotech Co., Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Shiyu Chen | China International Capital Corporation Limited |
| Wei Sun | China Merchants Securities Co. Ltd. |